ITC LTD

Q4FY25

Revenue ₹20,376 crores 🔼 10%

PAT ₹19,808 crores 🔼 282%

FY25

Revenue ₹81,613 crores 🔼 11%

PAT ₹35,053 crores 🔼 69%

ITC Ltd. delivered a resilient performance in FY25 despite a subdued demand environment and steep input cost inflation. The FMCG–Others segment posted a 4.8% revenue increase for the full year, led by robust growth in atta, spices, frozen snacks, dairy, premium personal wash, homecare, and agarbattis, though notebooks were hit by intense local competition. Cigarettes saw 7.1% revenue growth, supported by volume-led gains and portfolio enhancements, despite cost pressures from leaf tobacco. The agri business recorded strong growth, with revenue and segment profit rising 25% and 18%, respectively, driven by leaf tobacco and value-added exports.

During the year, ITC demerged its Hotels business into ITC Hotels Ltd. and announced key FMCG acquisitions like 24 Mantra Organic, Mother Sparsh, and Prasuma/Meatigo. 

The company declared final dividend of ₹7.85 per equity share. The  record date for the same is Wednesday, May 28, 2025.

Sun Pharmaceutical Industries Ltd

Q4FY25

Revenue ₹12,816 crores 🔼 8%

PAT ₹2,154 crores 🔻 19%

FY25

Revenue ₹52,041 crores 🔼 9%

PAT ₹10,965 crores 🔼 14%

Sun Pharmaceutical Industries Ltd. reported a strong financial performance for FY25, with consolidated revenue from operations rising 8% year-on-year and net profit rising 14.

The company continued to invest heavily in R&D, spending ₹3,248 crores during the year. Additionally, Ms. Vidhi Shanghvi was appointed as a Whole-time Director, while Mr. Sudhir Valia announced his retirement from the board.

Sun Pharma maintained leadership in chronic therapies in India, saw growth in the US specialty business, and continued expanding in emerging markets. Despite global macroeconomic challenges, the company’s diversified product mix and prudent financial management helped drive stable performance.

The board has recommended a final dividend of ₹5.50 per equity share, subject to shareholder approval.

Grasim Industries Ltd

Q4FY25

Revenue ₹44,267 crores 🔼 17%

PAT ₹1,496 crores 🔼 9%

FY25

Revenue ₹1,48,478 crores 🔼 13%

PAT ₹3,902 crores 🔻34%

Grasim Industries Ltd. delivered a strong performance in FY25, with consolidated revenue growing 17%. Growth was led by building materials (UltraTech Cement), chemicals, and financial services (Aditya Birla Capital), while profitability was tempered by ongoing investments in new businesses like paints and B2B e-commerce.

The B2B e-commerce venture, Birla Pivot, crossed an annualized revenue run-rate of ₹5,000 crores. UltraTech’s cement capacity reached 190.16 MTPA, and domestic volumes rose 10% YoY in Q4. Financial services reported a 27% increase in lending book to ₹1.57 lakh crore, with total AUM up 17% YoY. 

The board recommended a dividend of ₹10 per equity share, subject to shareholder approval. 

Container Corporation of India Ltd

Q4FY25

Revenue ₹2,288 crores 🔻 2%

PAT ₹288 crores 🔻 5%

FY25

Revenue ₹8,887 crores 🔼 3%

PAT ₹1,260 crores 🔼 2%

Container Corporation of India Ltd. reported a stable financial performance for FY25. Consolidated revenue rose 3% year-on-year, while consolidated net profit grew 2%.

The EXIM segment contributed ₹5,734 crores to annual revenue, while the domestic business added ₹3,153 crore. The company’s capital employed rose to ₹3,153 crores, reflecting continued investments in infrastructure and network capacity.

The board recommended a final dividend of ₹2 per equity share. Additionally, a 1:4 bonus issue was approved, subject to shareholder approval. 

Metro Brands Ltd

Q4FY25

Revenue ₹643 crores 🔼 10%

PAT ₹95 crores 🔻 39%

FY25

Revenue ₹2,507 crores 🔼 6%

PAT ₹354 🔻 15%

Metro Brands Ltd. delivered a resilient performance in FY25, with consolidated revenue rising 6% YoY, driven by festive demand and a strong omnichannel presence. E-commerce (including omnichannel) revenue reached ₹259 crore for the year, growing 20.% YoY.

The company opened 79 stores and closed 9 during the year, crossing the milestone of 900 stores across 205 cities. Growth was supported by robust performance from in-house brands, which contributed 74% of store sales, and strong traction in Tier II/III cities. Key new initiatives included the launch of Foot Locker’s first store in India and a long-term exclusive partnership with global brand New Era. Additionally, the Fila brand was relaunched with a focus on local manufacturing to address BIS-related supply chain disruptions.

To mark its 70th anniversary, Metro Brands declared a special dividend of ₹14.50 per share.

Emcure Pharmaceuticals Ltd

Q4FY25

Revenue ₹2,116 crores 🔼 20%

PAT ₹197 crores 🔼 26%

FY25

Revenue ₹7,896 crores 🔼 19%

PAT ₹707 crores 🔼 34%

Emcure Pharmaceuticals Ltd. delivered a strong performance in FY25, with consolidated revenue from operations rising 19% YoY. This growth was driven by solid performance across both domestic and international markets.

In India, domestic business revenue grew 24.8% YoY in Q4, led by the Women’s Health and Cardio segments, with new categories like Dermatology and OTC also contributing. International business rose 15.6% YoY. European operations benefited from new product approvals and a recently acquired portfolio.

The board has proposed a final dividend of ₹3 per equity share, subject to shareholder approval. 

Honasa Consumer Ltd

Q4FY25

Revenue ₹534 crores 🔼 13%

PAT ₹25 crores 🔼 5%

FY25

Revenue ₹2,067 crores 🔼 8%

PAT ₹73 crores 🔼 4%

Honasa Consumer Ltd. reported a solid Q4FY25 performance, with revenue rising 13.3%. The company posted a volume-led growth (UVG) of 21.2% for the quarter.

For FY25, revenue grew 8%. Mamaearth, the flagship brand, witnessed strong momentum across e-commerce and modern trade channels, entering the top 5 in face wash market share and expanding retail reach by 26% YoY to 2.36 lakh outlets. Contribution from direct distributors surged to 71% in Q4FY25.

Younger brands like The Derma Co. grew over 30% YoY, with its offline business crossing ₹100 crore ARR. The company also launched several first-to-India skincare innovations under The Derma Co. and Dr. Sheth’s, enhancing its prestige product portfolio.

Disclaimer

Investments in securities market are subject to market risks, read all the related documents carefully before investing. This is for informational purposes and should not be considered as recommendations.

Kindly refer to  https://share.market/ for more details.

PhonePe Wealth Broking Private Limited is a member of NSE & BSE with SEBI Regn. No.: INZ000302639, Depository Participant of CDSL Depository with SEBI Regn. No.: IN-DP-696-2022, Research Analyst with SEBI Regn No: INH000013387, BSE RA Enlistment Number: 5887, and Mutual Fund distributor with AMFI Registration No: ARN- 187821. Member ID: BSE- 6756, NSE- 90226. 

Registration granted by SEBI, enlistment as Research Analyst, and Certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered office – 2, Floor 3, Wing A, Block A, Salarpuria Softzone, Service Road, Green Glen Layout, Bellandur, Bengaluru South, Bengaluru, Karnataka – 560103, INDIA.

CIN: U65990KA2021PTC146954.